A A+ A A A

CBmed NEWS

10-12-2017 - Nagoya University as Partner of CBmed

The Nagoya University is now officially partner of CBmed in the 2nd funding period. Dr. Koji Yamanaka (Head of Institute for Neuroscience & Pathobiology) has signed for it.

Additionally, a meeting took place with the president Dr. Seiichi Matsuo, who heads the Nagoya University as well as the Nagoya Medical School. 

09-2017 Success with biomarkers

An article about CBmed GmbH entitled "Erfolg mit Biomarkern" has been published in Spirit: Potentiale - Science & Innovation.

Read the full article here.

08-23-2017 - SAP Health Story: CBmed

CBmed is using SAP Health solutions to pull value from patient data to identify more precise treatment options for patients.

 

For more information see the following video!

07-12-2017 - Improved mouse models for cancer research

In Graz, pathologists are developing a mouse model with which they want to predict whether a drug is effective against tumors. They also want to better understand the resistance to therapies.

Read the full article here.

 

07-11-2017 - CBmed works with SAP

CBmed to Implement SAP® Connected Health to Improve Processing of Large-Scale Clinical Data Sets.

Comprehensive project integrates biomarkers with data collected in EHRs to enable more effective re-use in routine patient care, research and clinical trial recruitment.

Read here the full article in "der Standard".

5-11-2017 - CBmed participated in the Business-Marathon at Schwarzlsee

This year, Thursday 11th of May 2017, CBmed successfully took part in the Business-Marathon again with eight people (Lucas Pflanzl, Christoph Haudum, David Merle, Michael Maximilian Schober, Robert Fasching, Isabell Dolznig, Karin Mattersdorfer and Sophie Narath) at Schwarzlsee.

02-13-2017 Biomarker Conference in Graz

On February 13th, 2017, the second CBmed Biomarker Conference took place in Graz. 

 

Maßgeschneiderte Medizin

Maßgeschneiderte Medizin: Biomarker-Experten tagen in Graz
13.02.2017


Graz (APA) - Etliche Medikamente und Therapien wirken bei einigen Patienten sehr gut, bei anderen nur eingeschränkt oder auch gar nicht. Von sogenannten Biomarkern verspricht man sich genauere Diagnostik, sie sollen aber auch bei der Verlaufskontrolle Verbesserungen bringen. Österreichweit ist das CBmed in Graz ganz vorne in der Biomarkerforschung dabei und veranstaltet ab 13. Februar eine internationale Konferenz.


Die personalisierte Medizin zielt darauf ab, die Wirksamkeit medizinischer Behandlungen zu verbessern: Durch präzise Diagnostik der Erkrankungen und ihren jeweiligen Varianten und dem Einsatz von Therapieverfahren, die daraufhin maßgeschneidert sind, schilderte Robert Fasching, wirtschaftlicher Geschäftsführer des K1-Kompetenzzentrums CBmed in Graz im Gespräch mit der APA. Forscher weltweit versuchen daher, sich immer näher an die molekularen und biochemischen Ursachen von Erkrankungen heranzutasten und im Genom, im Stoffwechsel (Metabolom) oder im Mikrobiom der Patienten biologisch messbare Indikatoren - sogenannte Biomarker - zu finden. An die 150 dieser Experten haben sich nun zur zweiten internationalen Biomarkerkonferenz in Graz auf Einladung des CBmed getroffen.


Enge Kooperation mit Grazer Meduni


Das Kompetenzzentrum für Biomarkerforschung startete im Jänner 2015 seinen Betrieb. In unmittelbarer Nähe zur Medizinischen Universität Graz, die Mehrheitseigentümerin des Zentrums ist, werden Technologien entwickelt und angewendet, die Volkskrankheiten wie Krebs, Diabetes, Hepatitis oder Herz- und Lebererkrankungen über entsprechende biologische Marker früher und besser diagnostizieren, um präziser behandeln zu können. Als wissenschaftliche Basis kommt den Forschern auch die Biobank an der Medizinischen Universität Graz, eine der größten Sammlungen biologischer Proben Europas, zugute.
Aktuell habe man an die 20 Forschungsprojekte in Arbeit. Nach zwei Jahren habe man laut Fasching erste Ergebnisse und drei Patente angemeldet, die sowohl für die Diagnose als auch Prognose von Krebs und Lungenhochdruck Verbesserungen bringen sollen. "Wir werden noch in diesem Jahr zeigen, wie sich durch die Kombination verschiedener Technologien bessere Ergebnisse in Diagnostik und Prognose bringen lassen", kündigte Fasching an.

 

Breite Forschungsplattform


"Wir sind vor zwei Jahren mit rund 20 wissenschaftlichen und 30 Industrie-Partnern gestartet, alleine im vergangenen Jahr sind sieben Partner hinzugekommen", schilderte der Geschäftsführer die Entwicklung des Zentrums. Zu den Partnern zählen u.a. B. Braun Melsungen, Eli Lilly, Merck Sharp & Dohme, Qiagen aber auch IT-Unternehmen wie Infineon und Kapsch BusinessCom. 2017 werde vor allem die Internationalisierung in Richtung Japan und den USA ein Schwerpunkt sein. Ende des Vorjahres wurde bereits ein Consultant für Japan eingesetzt, der die Pläne für ein künftiges Entwicklungszentrum in Japan vorantreiben soll. Ähnliche Pläne würden auch für den nordamerikanischen Bereich geschmiedet.
Vision von CBmed sei es, sich bis zum Jahr 2030 "ein weltweit führendes Zentrum für Biomarkerforschung im Bereich der personalisierten Medizin für Krebs, Stoffwechsel und Entzündungen" zu werden. Das Fördervolumen in der ersten Periode bis 2018 beläuft sich auf rund 17,4 Millionen Euro.

2-14-2017 - Consortium Board Meeting

On February 14th, 2017, the 3rd Consortium Board Meeting (for Consortium Members of CBmed only) will take place in Graz. 

01-01-2017 - Welcome at CBmed

We welcome Wolfgang Wadsak, PhD as Scientific Leader Area 1 "Data & Technologies", M.D. Harald Sourij in the function as "R&D Global Footprint" and Mag. Julia Mühl as CBmed HQ team assistance at CBmed.

11-29 and 11-30-2016 - 6th Munich Biomarker Conference

CBmed GmbH takes part in the 6th Munich Biomarker Conference this year and will be represented by Ing. Robert Fasching and Mag. Thomas Weber. 

 

CBmed consultant in Japan

We welcome Tim Kendall as our CBmed consultant in Japan.

Contact: tim.kendall@cbmed.org

GeneReader NGS System

Professor Kurt Zatloukal, from the Institute of Pathology at the Medical University of Graz, talked about his experiences of working with the GeneReader NGS System at CBmed. 

Here you find the entire talk. 

10-10-2016 - Introduction to CBmed in Vienna

On October 10, 2016 journalists were invited to CBmed in Vienna, where they got more detailed insight into the research laboratories as well as on the research priorities of CBmed in Vienna. 

 

For more details read the articles 1 and 2.

09-12-2016 - CBmed coordinator Vienna appointed

Prof. Wolfgang Wadsak, Head of Medical Radiochemistry and Biomarker Development at MUV has been appointed as CBmed Coordinator Vienna. 
His further tasks will include the implementation of the CBmed business strategy in Vienna & the representation of the CBmed Vienna technology focus at national and international meetings. He will serve as the main contact person in Vienna for funding bodies.

 

 

07-08-2016 - Press Conference in Vienna

On July 8, 2016 CBmed was appointed the European First Expert Center of the network European biobanks BBMRI - ERIC (biobanks and biomolecular resources research infrastructure - European Research Infrastructure Consortium) and officially launches a new Core Lab at the Medical University of Vienna. Together with cooperation partners TissueGnostics and Merck Sharp & Dohme GmbH (MSD) completely new methods are used for identification of new biomarkers. This represents a big step into personalized medicine, in particular to treat cancer patients.

 

 

First trusted expert center of BBMRI-ERIC

It is a pleasure to announce that CBmed was named the first expert center of BBMRI-ERIC. 

For more information see Press Release - 06.2016.

5-12-2016 - CBmed participated in the Business-Marathon at Schwarzlsee

This year, 12th of May 2016, CBmed successfully took part in the Business-Marathon with eight people (Isabell Dolznig, Maria Smolle, Angela Jacan, Elke Pacher, Petra Majcen, Richard Ackbar, Kaddour Bounab und Christian Peitler) at Schwarzlsee.

Lange Nacht der Forschung 2016

Lange Nacht der Forschung was a great event again. Many interested people performed experiments and had talks with researchers and scientists.
This year, CBmed participated in this great event for the first time. Here are a few impressions of lange Nacht der Forschung at CBmed.

04-22-2016 - This year the "Lange Nacht der Forschung" also at CBmed

This year, Austria's largest research event "Lange Nacht der Forschung" will again take place. There are some exciting locations where the interested public can meet with researchers and scientists to openly discuss the latest research. Lange Nacht der Forschung 2016 offers an extensive and exciting program, including presentations, guided tours and interactive stations/join-in activities, providing an insight into the world of research.

Take the chance to experience exciting developments and the newest technologies first hand.

Interactive experience of digital pathology in biomarker research

CBmed GmbH links the expertise of the Medical University of Graz and Vienna with technology of international leading pharmaceutical, diagnostics and medical technology companies. The aim is to improve diagnosis and treatment of cancer, metabolic diseases and inflammation. Along with scientific and industrial partners, solutions are developed for the care of patients.

By viewing thin tissue sections via microscope, a pathologist can tell a lot about a person and his or her diseases. New methods have been developed over decades, which allow pathologists not only to recognize/detect the shape and structure of tissue, but also to identify proteins and genes.

At CBmed visitors can interactively experience how microscopy images are generated and digitalized, and subsequently how computer software helps scientists to find new ways of analyzing cells from patients.

When: 22/04/2016 from 6 pm until 11 pm

Where: CBmed GmbH, Stiftingtalstraße 5, 8010 Graz

For more information, please visit: http://www.langenachtderforschung.at

02-11-2016 First CBmed Biomarker Conference in Graz

The 1st CBmed Biomarker Conference took place in Graz on Thursday, 11th February 2016.

02-08-2016 - QIAGEN und Kapsch besiegeln zukunftsweisende Kooperation mit Forschungszentrum CBmed in der Biomarker Analyse

Weltweit erste Komplettlösung für Biomarker-Analyse geht an der Med Uni Graz in Betrieb.

Graz (Österreich), 8. Februar 2016 – Qiagen GmbH Deutschland liefert als weltweit führender Anbieter die erste durchgängige Komplettlösung in der medizinischen Diagnostik  für den gesamten Gensequenzierungsprozess nach Graz, wo sie vom Forschungszentrum CBmed in Betrieb genommen wird. Das völlig neue Konzept setzt neue Maßstäbe in der Standardisierung und Qualitätssicherung bei Gensequenz-Analysen in der medizinischen Diagnostik. Dies wird für die Erkennung und Behandlung von beispielsweise Krebserkrankungen richtungsweisend sein. Kapsch BusinessCom tritt dem internationalen Forschungs-Konsortium des CBmed bei und steigt in die Sicherung der großen anfallenden Datenmengen ein.

Full Text of Press Release

Infektiologie: WissenschafterInnen ausgezeichnet (de)

WissenschafterInnen der Med Uni Graz bei internationalen Infektiologischen Kongressen erfolgreich.

WissenschafterInnen der Med Uni Graz konnten bei der 55. ICAAC 2015 (Interscience Conference on Antimicrobial Agents and Chemotherapy) in San Diego und dem 7. TIMM 2015 (Trends in Medical Mycology) in Lissabon zahlreiche Preise gewinnen. Diese wurden von einem wissenschaftlichen Komitee nach inhaltlicher Begutachtung der eingereichten Abstracts zuerkannt.

Dr. Jürgen Prattes, Sektion für Infektiologie und Tropenmedizin, Universitätsklinik für Innere Medizin und CBmed Graz, erhielt bei der ICAAC ein „ID Fellows Grant Program" für seine drei Posterpräsentationen. Er war damit einer von 15 nicht-US PreisträgerInnen.Jürgen Prattes konnte zusätzlich mit einem von der Med Uni Graz und CBmed betriebenen Forschungsprojekt "Serum 1, 3-Beta-D-Glucan Levels are Not Influenced by Hemodialysis or Hemodiafiltration" beim TIMM 2015 als einer von 5 internationalen PreisträgerInnen den „ECMM Young Investigator Travel Award" gewinnen.

Dr.in Frederike Reischies, Sektion für Infektiologie und Tropenmedizin, Universitätsklinik für Innere Medizin (seit 01.10.15 Klinische Abteilung für Plastische, Ästhetische und Rekonstruktive Chirurgie), und Dr.inSusanne Eigl, Klinische Abteilung für Pulmonologie und Sektion für Infektiologie und Tropenmedizin, Universitätsklinik für Innere Medizin, erhielten bei der ICAAC 2015 den Post-Doctoral Travel Grant mit den Arbeiten "Calculation of the Galactomannan-Creatinine Index Improves the Diagnostic Performance of Galactomannane Testing from Urine Samples", "Prognostic Potential of 1,3-Beta-D-Glucan Levels in Bronchoalveolar Lavage Fluid Samples", "Diagnostic performance of 1,3-Beta-D-Glucan Serum Screening in Patients receiving Hematopoietic Stem Cell Transplantation" (Dr. Reischies; 1 Vortrag, 2 Posterpräsentationen) und "Galactomannan Testing and Aspergillus PCR in same-day bronchoalveolar lavage and blood samples obtained from patients with hematological malignancies at risk for invasive mould infection" (Dr. Eigl; 1 Posterpräsentation).

Wir gratulieren den PreisträgerInnen herzlich zu diesem Erfolg!

06-29-2015 - Press Release: CBmed teaming up with Dutch Amarna Therapeutics in the development of immunotherapies

Graz and Leiden, The Netherlands, June 29th 2015 – Graz based Center for Biomarker Research in Medicine (CBmed), today announced that it has entered into a cooperation with Dutch Amarna Therapeutics, for the development of immunotherapies against acute lymphoblastic leukemia (ALL), obesity, diabetes mellitus type 2 (DM2) and atherosclerotic cardiovascular disease (ASCVD). Amarna Therapeutics is a privately held Leiden based biotechnology company developing a next-generation viral vector platform that could play a key role in transforming treatment across many disease areas.

The agreement includes the design, development and testing in two separate projects of a CAR T-cell therapy and reverse vaccines for the treatment of these major diseases with high unmet clinical needs. Amarna will contribute its proprietary SVac viral gene delivery vector platform to this collaboration and CBmed will perform in-vitro and in-vivo preclinical R&D and develop cutting-edge immunological assays in its core laboratory.

Immunotherapies hold an enormous potential as novel treatment options for a wide range of diseases, including cancer and degenerative diseases such as obesity, DM2 and ASCVD. The objective of this collaboration is to test Amarna’s SVac vector platform for its capacity to modulate immune responses in humans with the final aim to develop efficient treatment options for cancer, diabetes and cardiovascular diseases.

Thomas Pieber, CSO of CBmed: "Biomarkers play a crucial role in the development of new therapeutic and preventive agents. This cooperation is a wonderful opportunity for CBmed to investigate novel biomarkers alongside the identification of new therapeutic targets for the innovative treatment approaches of Amarna Therapeutics."

Ben van Leent, CEO of Amarna"We are excited to extend our pipeline of products and launch activities in these important disease areas. We are convinced that the combination of the technology platform from Amarna Therapeutics and the scientific and medical expertise of CBmed will lead to the development of breakthrough solutions for a large group of immunity-associated diseases.”

CAR T-cell therapy            
In CAR T-cell therapies, engineered chimeric antigen receptors (CARs) with specificity for a tumor-specific cell surface protein (tumor antigen) are transferred to CD8+ T cells sampled from cancer patients. The CD8+ T cells expressing the CARs will specifically target and destroy the patient’s tumor cells, thereby attempting to cure the patient from cancer. In this collaboration, an SVac vector encoding a CAR which is specific for CD19 and present on B-cells, will be tested for its efficacy to treat ALL as a proof-of-principle for SVac-based CAR T-cell therapies to treat cancer.

SVac-based reverse vaccines
Vaccines are routinely used to induce immune responses against pathogens to protect humans from pathogen infection. Reverse vaccines are used to stop existing immune responses in patients with degenerative diseases. Liver-specific expression of the self-protein (self-antigen) involved in autoimmune tissue destruction using a viral gene delivery vector is by far the most efficient way to stop an existing immune response against a specific self-antigen. Because of its non-immunogenicity in humans, Amarna’s SVac gene delivery platform is unique in its capacity to stop immune responses in patients and therefore it is ideally suited for the use in reverse vaccines to treat degenerative diseases. 

3-18 and 3-19-2015 CBmed invited to Boehringer Ingelheim

On the 18th-19th of March 2015, CBmed GmbH were invited, as part of a 27-member delegation of the Styrian Human Technology Cluster, by Christoph Boehringer (Member of the Shareholders' Committee), Stefan Rinn (CEO) and Volker Bargon (Head of Global Procurement) to Boehringer Ingelheim’s research and development site in Biberach an der Riss.

CBmed presented their expertise and technology platforms in cancer and metabolism including analysis of the immune system in metabolomic disease and cancer, microbiome studies and the detection of minimal residual disease. 

Such events further highlight Styria as a hot bed for Human Life Science Technology and Innovation. Located in the south-east of Austria, Styria is one of the most attractive economic regions in Europe for technology investment and has developed a global reputation in the fields of: 

- Biobanking and biomarker technologies
- Process engineering for pharmaceutical and biotechnology companies
- Advanced biomedical sensor technologies

To find out more about Life Sciences in Styria, visit Human Technology Styria.

Visit to Boehringer Ingelheim:The delegation from Styria, Austria, including representatives from CBmed GmbH and their scientific partners, meet with colleagues from Boehringer Ingelheim.

Christoph Boehringer (3rd from left), Member of the Shareholders' Committee, meets Johann Harer (2nd from left), Managing director of the Human Technology Styria Cluster, and Stefan Rinn (left), Boehringer Ingelheim’s CEO, as well as Volker Bargon (right), Head of Global Procurement by Boehringer Ingelheim, in Biberach.

03-23-2015 - Press Conference with Industry Representatives

The CBmed board met with Dr. Tim Heise (Profil Germany, Chairman of the CBmed Consortium Board) and Dr. Martin Ellmerer (B. Braun Austria) on March 23rd, 2015.

01-22 and 01-23-2015 - Consortium meetings

Consortium Meeting 22.1.2015
Consortium Board Meeting 23.1.2015

01-21-2016 - Opening Ceremony

The CBmed core lab opening ceremony took place on Wednesday, 21st January 2015 with shareholders and supporters.

Past achieved milestones

Major milestones achieved in 2014:
  • CBmed GmbH (ltd.) foundation Sept. 30, 2014
  • CEO nominations: Prof. Thomas Pieber CSO, Ing. Robert Fasching CFO
  • Aquisition of the new CBmed Core lab facility (500m2) on Oct. 20th, located at Stiftingtalstraße 5, 8010 Graz
  • Consortium Agreement signed by 63% of original Company Partners and 75% of original Scientific Partners by Dec. 22, 2014 resulting in fulfillment of Funding Agencies start up conditions!
  • FFG Funding start up rate received on Dec. 31st, 2014